E-cadherin gene promoter hypermethylation may contribute to the risk of bladder cancer among Asian populations

Gene

Volumn 534, Issue 1, 2014, Pages 48-53

  Li, Gang ^a   Liu, Yili ^a   Yin, Huming ^a   Zhang, Xuefeng ^a   Mo, Xiaodong ^a   Tang, Jing ^a   Chen, Weiguo ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Bladder cancer; E cadherin; Hypermethylation; Meta analysis

Indexed keywords

UVOMORULIN;

ARTICLE; ASIAN; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER RISK; CAUCASIAN; CHINA; DNA METHYLATION; GENE FUNCTION; GENETIC HETEROGENEITY; HUMAN; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; QUALITY CONTROL; SYSTEMATIC REVIEW; TAIWAN; UNITED KINGDOM; UNITED STATES; UROTHELIUM;

ASIAN CONTINENTAL ANCESTRY GROUP; CADHERINS; DNA METHYLATION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROMOTER REGIONS, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 84888026182     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.10.027     Document Type: Article

References (43)

1. Bangma C.H., et al. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur. Urol. 2013, 64:41-47.
2. Bornman D.M., Mathew S., Alsruhe J., Herman J.G., Gabrielson E. Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am. J. Pathol. 2001, 159:831-835.
3. Chan M.W., et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 2002, 8:464-470.
4. Chang D.W., Gu J., Wu X. Germline prognostic markers for urinary bladder cancer: obstacles and opportunities. Urol. Oncol. 2012, 30:524-532.
5. Chen P.C., et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med. Genet. 2011, 4:45.
6. Cheng L., Zhang S., MacLennan G.T., Williamson S.R., Lopez-Beltran A., Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum. Pathol. 2011, 42:455-481.
7. Chik F., Szyf M., Rabbani S.A. Role of epigenetics in cancer initiation and progression. Adv. Exp. Med. Biol. 2011, 720:91-104.
8. Christofori G., Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci. 1999, 24:73-76.
9. Chung W., et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1483-1491.
10. Dong Z.T., et al. Promoter methylation of E-cadherin gene in the bladder epithelium of patients with bladder cancer. Chin. J. Exp. Surg. 2003, 20:1149.
11. Dudziec E., Goepel J.R., Catto J.W. Global epigenetic profiling in bladder cancer. Epigenomics 2011, 3:35-45.
12. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21:5427-5440.
13. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.
14. Friedrich M.G., et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur. J. Cancer 2005, 41:2769-2778.
15. Hoque M.O., et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl. Cancer Inst. 2006, 98:996-1004.
16. Ioannidis J.P., Patsopoulos N.A., Rothstein H.R. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ 2008, 336:1413-1415.
17. Jackson D., White I.R., Riley R.D. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat. Med. 2012, 31:3805-3820.
18. Jeanes A., Gottardi C.J., Yap A.S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene 2008, 27:6920-6929.
19. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
20. Kamat A.M., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur. Urol. 2013, 63:4-15.
21. Kim W.J., Bae S.C. Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 2008, 99:646-652.
22. Kulis M., Esteller M. DNA methylation and cancer. Adv. Genet. 2010, 70:27-56.
23. Latini D.M., Lerner S.P., Wade S.W., Lee D.W., Quale D.Z. Bladder cancer detection, treatment and outcomes: opportunities and challenges. Urology 2010, 75:334-339.
24. Li L., Bennett S.A., Wang L. Role of E-cadherin and other cell adhesion molecules in survival and differentiation of human pluripotent stem cells. Cell Adh. Migr. 2012, 6:59-70.
25. Lin H.H., Ke H.L., Wu W.J., Lee Y.H., Chang L.L. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection. Urol. Oncol. 2012, 30:177-181.
26. Lopez-Serra P., Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 2012, 31:1609-1622.
27. McConkey D.J., et al. Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol. Oncol. 2010, 28:429-440.
28. Mitra A.P., Cote R.J. Molecular pathogenesis and diagnostics of bladder cancer. Annu. Rev. Pathol. 2009, 4:251-285.
29. Pelucchi C., Bosetti C., Negri E., Malvezzi M., La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol. 2006, 3:327-340.
30. Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006, 295:676-680.
31. Pu R.T., Laitala L.E., Clark D.P. Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol. 2006, 50:499-506.
32. Ribeiro-Filho L.A., et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol. Carcinog. 2002, 34:187-198.
33. Roupret M., et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract. Actas Urol. Esp. 2012, 36:2-14.
34. Serre D., et al. Correction of population stratification in large multi-ethnic association studies. PLoS One 2008, 3:e1382.
35. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25:603-605.
36. Sun J., et al. Hypermethylated SFRP1, but none of other nine genes "informative" for western countries, is valuable for bladder cancer detection in mainland China. J. Cancer Res. Clin. Oncol. 2009, 135:1717-1727.
37. van Vlodrop I.J., et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location!. Clin. Cancer Res. 2011, 17:4225-4231.
38. Virani S., Colacino J.A., Kim J.H., Rozek L.S. Cancer epigenetics: a brief review. ILAR J. 2012, 53:359-369.
39. Wierstra I. The transcription factor FOXM1c binds to and transactivates the promoter of the tumor suppressor gene E-cadherin. Cell Cycle 2011, 10:760-766.
40. Wu Z.Y., et al. Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis. World J. Gastroenterol. 2005, 11:3139-3143.
41. Yates D.R., et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 2007, 13:2046-2053.
42. Zhang X., Ma X., Zhu Q.G., Li L.C., Chen Z., Ye Z.Q. Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J. Urol. 2003, 170:1379-1382.
43. Zhao M., Li Z., Yu Y.C., Duan J.M., Li J.H. Analysis of CpG island methylation status of E-cadherin gene in bladder cancer. Lab. Med. 2005, 20:55-58.